FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078126089> ?p ?o ?g. }

• W2078126089 endingPage "825" @default.
• W2078126089 startingPage "819" @default.
• W2078126089 abstract "The current study assessed the efficacy and safety of biweekly oxaliplatin combining oral tegafur-uracil/leucovorin in treating chemonaive patients with advanced gastric cancer.Eligible patients were 18-75 years old, had stage IV disease or post-surgery recurrence, no prior palliative chemotherapy, and an ECOG performance status of 0-2. Patients in the current study received 2-h i.v. infusion of oxaliplatin at a dose of 100 mg/m(2) after diluting in 500 mL 5% dextrose/water (dexan premedication), and 5-HT3 antagonist biweekly. Oral tegafur-uracil and leucovorin was given at a dose of 300 mg/m(2)/day and 60 mg/day three times daily from day 1 to 21, respectively, followed by a 1-week rest. Response assessment was based on the RECIST criteria and was performed every two courses. Toxicity was assessed according to NCI common toxicity criteria version 2.From October 2003 to April 2006, 57 patients were evaluated (55 eligible) with a median age of 61 years (range 31-75). According to the assessment of response in 48 evaluable patients, partial response rate was 24/48 (50.0%) (95% CI: 35.23-64.73%) and stable disease was observed in 11 patients (22.92%), and diseased progressed in 13 patients (27.08%). Mean number of oxaliplatin cycles was 3 (0.5-6.5). Median time to progression was 177 days. Median overall survival was 318 days. Major-grade (III/IV) toxicities were diarrhea 25.5%, vomiting 16.5%, anemia 10.9%, numbness 12.7%, thrombocytopenia 7.3%, neutropenia 3.6% and leucopenia 1.8%.Biweekly, oxaliplatin combining oral tegafur-uracil/leucovorin in treating patients with advanced gastric cancer showed acceptable activity and manageable toxicity." @default.
• W2078126089 created "2016-06-24" @default.
• W2078126089 creator A5012200456 @default.
• W2078126089 creator A5037393858 @default.
• W2078126089 creator A5042014850 @default.
• W2078126089 creator A5042553271 @default.
• W2078126089 creator A5044063680 @default.
• W2078126089 creator A5045103654 @default.
• W2078126089 creator A5048193997 @default.
• W2078126089 creator A5060611572 @default.
• W2078126089 creator A5087768741 @default.
• W2078126089 creator A5088098414 @default.
• W2078126089 date "2008-07-29" @default.
• W2078126089 modified "2023-09-26" @default.
• W2078126089 title "A multiple-center phase II study of biweekly oxaliplatin and tegafur–uracil/leucovorin for chemonaive patients with advanced gastric cancer" @default.
• W2078126089 cites W1903827874 @default.
• W2078126089 cites W1982336200 @default.
• W2078126089 cites W1999562420 @default.
• W2078126089 cites W2008575122 @default.
• W2078126089 cites W2011391447 @default.
• W2078126089 cites W2018925207 @default.
• W2078126089 cites W2019162272 @default.
• W2078126089 cites W2020830322 @default.
• W2078126089 cites W2028547579 @default.
• W2078126089 cites W2033465919 @default.
• W2078126089 cites W2035075389 @default.
• W2078126089 cites W2035185002 @default.
• W2078126089 cites W2059830719 @default.
• W2078126089 cites W2078498260 @default.
• W2078126089 cites W2078510679 @default.
• W2078126089 cites W2092470860 @default.
• W2078126089 cites W2105034700 @default.
• W2078126089 cites W2122866527 @default.
• W2078126089 cites W2122879222 @default.
• W2078126089 cites W2123495698 @default.
• W2078126089 cites W2128328462 @default.
• W2078126089 cites W2128775037 @default.
• W2078126089 cites W2128941960 @default.
• W2078126089 cites W2130522735 @default.
• W2078126089 cites W2131463911 @default.
• W2078126089 cites W2139248078 @default.
• W2078126089 cites W2161563098 @default.
• W2078126089 cites W2329838159 @default.
• W2078126089 doi "https://doi.org/10.1007/s00280-008-0797-4" @default.
• W2078126089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18663448" @default.
• W2078126089 hasPublicationYear "2008" @default.
• W2078126089 type Work @default.
• W2078126089 sameAs 2078126089 @default.
• W2078126089 citedByCount "5" @default.
• W2078126089 countsByYear W20781260892013 @default.
• W2078126089 countsByYear W20781260892019 @default.
• W2078126089 countsByYear W20781260892021 @default.
• W2078126089 crossrefType "journal-article" @default.
• W2078126089 hasAuthorship W2078126089A5012200456 @default.
• W2078126089 hasAuthorship W2078126089A5037393858 @default.
• W2078126089 hasAuthorship W2078126089A5042014850 @default.
• W2078126089 hasAuthorship W2078126089A5042553271 @default.
• W2078126089 hasAuthorship W2078126089A5044063680 @default.
• W2078126089 hasAuthorship W2078126089A5045103654 @default.
• W2078126089 hasAuthorship W2078126089A5048193997 @default.
• W2078126089 hasAuthorship W2078126089A5060611572 @default.
• W2078126089 hasAuthorship W2078126089A5087768741 @default.
• W2078126089 hasAuthorship W2078126089A5088098414 @default.
• W2078126089 hasBestOaLocation W20781260891 @default.
• W2078126089 hasConcept C121608353 @default.
• W2078126089 hasConcept C126322002 @default.
• W2078126089 hasConcept C141071460 @default.
• W2078126089 hasConcept C2776694085 @default.
• W2078126089 hasConcept C2776907518 @default.
• W2078126089 hasConcept C2777063308 @default.
• W2078126089 hasConcept C2777299880 @default.
• W2078126089 hasConcept C2778248108 @default.
• W2078126089 hasConcept C2778496288 @default.
• W2078126089 hasConcept C2778822529 @default.
• W2078126089 hasConcept C2778850193 @default.
• W2078126089 hasConcept C2780852908 @default.
• W2078126089 hasConcept C2780962732 @default.
• W2078126089 hasConcept C31760486 @default.
• W2078126089 hasConcept C526805850 @default.
• W2078126089 hasConcept C71924100 @default.
• W2078126089 hasConcept C90924648 @default.
• W2078126089 hasConceptScore W2078126089C121608353 @default.
• W2078126089 hasConceptScore W2078126089C126322002 @default.
• W2078126089 hasConceptScore W2078126089C141071460 @default.
• W2078126089 hasConceptScore W2078126089C2776694085 @default.
• W2078126089 hasConceptScore W2078126089C2776907518 @default.
• W2078126089 hasConceptScore W2078126089C2777063308 @default.
• W2078126089 hasConceptScore W2078126089C2777299880 @default.
• W2078126089 hasConceptScore W2078126089C2778248108 @default.
• W2078126089 hasConceptScore W2078126089C2778496288 @default.
• W2078126089 hasConceptScore W2078126089C2778822529 @default.
• W2078126089 hasConceptScore W2078126089C2778850193 @default.
• W2078126089 hasConceptScore W2078126089C2780852908 @default.
• W2078126089 hasConceptScore W2078126089C2780962732 @default.
• W2078126089 hasConceptScore W2078126089C31760486 @default.
• W2078126089 hasConceptScore W2078126089C526805850 @default.
• W2078126089 hasConceptScore W2078126089C71924100 @default.
• W2078126089 hasConceptScore W2078126089C90924648 @default.

• next